Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.78−0.16 (-1.61%)
Close on Nov 17, 2026Market cap $561.73MP/E –Yield –
Climb Bio r&d expenses
Research and development expenses are spending on new products and technology.
Climb Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $41.90M, up 16.1% year over year. For fiscal 2025 it was $46.71M, up 225.8% from the year before. The highest annual figure on record is $46.71M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.71M | +225.8% |
| FY2024 | Dec 31, 2024 | $14.34M | -7.0% |
| FY2023 | Dec 31, 2023 | $15.41M | -41.2% |
| FY2022 | Dec 31, 2022 | $26.21M | +12.4% |
| FY2021 | Dec 31, 2021 | $23.32M | +166.0% |
| FY2020 | Dec 31, 2020 | $8.77M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.71M | +47.7% |
| Q1 FY2026 | Mar 31, 2026 | $9.37M | -45.9% |
| Q4 FY2025 | Dec 31, 2025 | $13.74M | +130.5% |
| Q3 FY2025 | Sep 30, 2025 | $9.07M | +45.4% |
| Q2 FY2025 | Jun 30, 2025 | $6.58M | +528.6% |
| Q1 FY2025 | Mar 31, 2025 | $17.33M | +1488.2% |
| Q4 FY2024 | Dec 31, 2024 | $5.96M | +90.6% |
| Q3 FY2024 | Sep 30, 2024 | $6.24M | +117.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.05M | -71.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.09M | -80.9% |
| Q4 FY2023 | Dec 31, 2023 | $3.13M | -36.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.88M | -32.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.69M | -57.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.72M | -30.8% |
| Q4 FY2022 | Dec 31, 2022 | $4.93M | -28.4% |
| Q3 FY2022 | Sep 30, 2022 | $4.26M | -28.9% |
| Q2 FY2022 | Jun 30, 2022 | $8.77M | +60.1% |
| Q1 FY2022 | Mar 31, 2022 | $8.26M | +93.3% |
| Q4 FY2021 | Dec 31, 2021 | $6.88M | +66.8% |
| Q3 FY2021 | Sep 30, 2021 | $5.99M | +210.3% |
| Q2 FY2021 | Jun 30, 2021 | $5.48M | +313.4% |
| Q1 FY2021 | Mar 31, 2021 | $4.27M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.13M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.93M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.33M | – |
See a number that looks wrong?